SCYX Stock — SCYNEXIS Inc.: Cash, EV, Pipeline

What they do

We are developing our proprietary antifungal platform “fungerps”, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis , Coccidioides , Histoplasma and Blastomyces genera and most common mucorales species.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.48

Market cap

$34.6M

Cash

$47.2M

Enterprise value

-$12.6M

Balance sheet

Cash	$47.2M
Debt	$0.0M
Net cash	$47.2M
Enterprise value	-$12.6M
Basic shares	9.9M shares
Fully diluted shares	14.6M shares
Fully diluted market cap	$50.7M
Cash per share	$4.74
Quarterly burn	$14.9M
Cash runway	3.2 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

9.9M

Pre-funded warrants

1.9M

Options

0.5M

RSUs

0.3M

Warrants

1.9M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

14.6M

Cap table as of 2026-11-01.

Price history

Loading SCYX daily closes…

Loading price history…

Next catalyst

SCY-770 (Phase 2) · Est. Sep 30, 2027 · half midpoint · guided in 8 mo

Recently reported

SCY-770 Phase 1 Mixed · 2026-10-06

Phase 1 food-effect/PK study · autosomal dominant polycystic kidney disease

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Sep 30, 2027 in 8 mo half midpoint	SCY-770 (Phase 2) Phase 2 proof-of-concept in ADPKD	Phase 2	ADPKD	H2 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

SCY-770

Phase 1 · Active Modality: oral small-molecule direct AMPK activator

Target AMPK

Partnerships Poxel: Asset Purchase Agreement; exclusive, sublicensable, perpetual, irrevocable worldwide license to certain Poxel IP

Indications

Autosomal dominant polycystic kidney disease (ADPKD) (Phase 1)

Catalysts

— Q3 2026
— Q4 2026
— H2 2027

Status note Lead program for ADPKD; previously evaluated in Phase 1 and a Phase 2a in NAFLD. Plan: Phase 1 confirmatory study Q3 2026, Phase 2 POC in ADPKD Q4 2026, early readout H2 2027.

SCY-247

Phase 1 · Active Modality: next-generation fungeRP antifungal

Target glucan synthase

Indications

Difficult-to-treat and drug-resistant fungal infections (Phase 1)

Catalysts

— Q3 2026

Status note Phase 1 oral and IV formulation studies; oral studies complete (88 healthy subjects, SAD/MAD); IV study initiated Q1 2026 with data anticipated Q3 2026.

BREXAFEMME

Approved · Active Modality: fungeRP antifungal

Aliases ibrexafungerp tablets

Target glucan synthase

Partnerships GSK (GlaxoSmithKline Intellectual Property (No. 3) Limited): licensed May 2023; NDA transfer completed Nov 2025; GSK to initiate regulatory interactions with FDA on US relaunch for VVC and refractory VVC. Hansoh (Greater China) and R-Pharm (Russian Federation and certain countries) commercialization collaborations

Indications

Vulvovaginal candidiasis (VVC) and reduction in incidence of recurrent VVC (Approved)

Status note First approved fungeRP (ibrexafungerp tablets). MARIO Phase 3 study of ibrexafungerp terminated Q4 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05908682	Not disclosed	Recruiting	Sponsor	SCYX	—	Vulvovaginal Candidiasis; Candida Infection; Vaginal Candidiasis	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Scynexis, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Great Point Partners	944,292	-6,610,055	0.91%	2026-08-14
DAFNA Capital	135,868	-951,088	0.11%	2026-08-14
ADAR1 Capital Management	49,387	+49,387	0.01%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

SCYX — SCYNEXIS Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

SCYX — SCYNEXIS Inc.